AKT1 and bipolar disorder: Together, the present study and our previous report [9] show that such drugs can affect mitochondrial movement directly via the Akt-GSK3 signaling pathway, which itself can be a direct therapeutic target, as in the administration of lithium to treat bipolar disorder.